ADDvise Q4 2023: Lower-than-expected sales, solid margins - Redeye

Redeye provides its initial take on ADDvise’s Q4 2023 report, which came in moderately below our estimates. We judge that positives from the report include strong organic Lab sales growth and margin expansion. Notable negatives include weaker-than-expected organic growth for Healthcare due to strong comparables for the pharmaceuticals segment, which we failed to anticipate. Overall, we judge that the company’s investment case remains essentially unchanged and expect to make limited changes to our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/983924/addvise-q4-2023-lower-than-expected-sales-solid-margins?utm_source=finwire&utm_medium=RSS